Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms

被引：0
|
作者：
Kremastiotis, Georgios
Efentakis, Panagiotis
Varela, Aimilia
Davos, Constantinos H.
Papanagnou, Eleni-Dimitra
Trougakos, Ioannis P.
Kastritis, Eftathios
Chavdoula, Evangelia
Iliodromitis, Efstathios
Klinakis, Apostolos
Dimopoulos, Meletios A.
Andreadou, Ioanna
Terpos, Evangelos
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3086
引用
收藏
页数：3
相关论文
共 20 条
  • [1] Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib
    Brian B. Hasinoff
    Daywin Patel
    Xing Wu
    Cardiovascular Toxicology, 2017, 17 : 237 - 250
  • [2] Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib
    Hasinoff, Brian B.
    Patel, Daywin
    Wu, Xing
    CARDIOVASCULAR TOXICOLOGY, 2017, 17 (03) : 237 - 250
  • [3] Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib
    Hasinoff, Brian B.
    Wu, Xing
    Patel, Daywin
    CANCER RESEARCH, 2016, 76
  • [4] Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib, carfilzomib, ixazomib, oprozomib, and delanzomib
    Hasinoff, Brian B.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] The proteasome inhibitor carfilzomib (Cfz) induces cardiotoxicity in vivo: molecular mechanisms and the cardioprotective effect of metformin (Met)
    Kremastiotis, G.
    Efentakis, P.
    Varela, A.
    Davos, C. H.
    Tsoumani, M.
    Papanagnou, E. D.
    Trougakos, I. P.
    Kastritis, E.
    Kanaki, Z.
    Iliodromitis, E. K.
    Klinakis, A.
    Dimopoulos, M. A.
    Terpos, E.
    Andreadou, I.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 120 : 33 - 33
  • [6] Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
    Efentakis, Panagiotis
    Kremastiotis, Georgios
    Varela, Aimilia
    Nikolaou, Panagiota-Efstathia
    Papanagnou, Eleni-Dimitra
    Davos, Constantinos H.
    Tsoumani, Maria
    Agrogiannis, Georgios
    Konstantinidou, Anastasia
    Kastritis, Efstathios
    Kanaki, Zoi
    Iliodromitis, Efstathios K.
    Klinakis, Apostolos
    Dimopoulos, Meletios A.
    Trougakos, Ioannis P.
    Andreadou, Ioanna
    Terpos, Evangelos
    BLOOD, 2019, 133 (07) : 710 - 723
  • [7] Investigating the molecular mechanisms of carfilzomib-induced cardiotoxicity and the emerging role of metformin as a prophylactic therapy
    Kremastiotis, G.
    Efentakis, P.
    Varela, A.
    Davos, C. H.
    Papanagnou, E. -D.
    Trougakos, I. P.
    Kastritis, E.
    Kanaki, Z.
    Iliodromitis, E. K.
    Klinakis, A.
    Dimopoulos, M. A.
    Terpos, E.
    Andreadou, I.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1003 - 1003
  • [8] Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
    Cheng, Mengfei
    Yang, Fang
    Liu, Jiahui
    Yang, Dan
    Zhang, Shuo
    Yu, Yang
    Jiang, Shuai
    Dong, Mei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [9] Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib
    Trougakos, Ioannis P.
    Papanagnou, Eleni-Dimitra
    Bagratuni, Tina
    Kastritis, Efstathios
    Papassideri, Issidora S.
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2014, 124 (21)
  • [10] Molecular mechanisms of bortezomib- and carfilzomib-induced apoptosis in B16-F1 melanoma cells
    Lee, M.
    Lim, S.
    Lee, S.
    Yeo, E.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
12